Oramed Pharmaceuticals, Inc. (ORMP)

NASDAQHealth CareBiotechnologySnapshot 2026-10-15

$4.07-2.63%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Oramed Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
successful completion of Phase III trials for ORMD-0801	Successful Phase II trials could lead to significant revenue.	Intact	failure to complete Phase III trials by FY27	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-08-27	Unavailable	Unavailable	1 / 1
2026-08-28	Unavailable	Unavailable	1 / 1
2026-08-29	Unavailable	Unavailable	1 / 1
2026-08-30	Unavailable	Unavailable	1 / 1
2026-08-31	Unavailable	Unavailable	1 / 1
2026-09-01	Unavailable	Unavailable

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

successful completion of Phase III trials for ORMD-0801Qualitative condition
maintaining a gross margin above 60%Published status: Broken
revenue growth returning to positive territoryRequired source inputs unavailable

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-23.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Oramed Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

ORMP represents a speculative growth investment with a medium confidence level. The current thesis state is cautious, as recent financial results have been weak, and the stock is under watch due to elevated risk factors.

What's priced into Oramed Pharmaceuticals, Inc.

The market seems to price in a cheap valuation compared to peers, but there are concerns about the company's fragile earnings quality and weak execution. The elevated valuation reflects a disconnect between current performance and market expectations.

What the fundamentals likely do

Fundamentals may continue to struggle in the near term, especially given the elevated probability of an earnings miss. Recent financial performance has been weak, and the company has not shown strong execution, which raises concerns.

What Oramed Pharmaceuticals, Inc. hinges on

The future of ORMP hinges on broader sector performance, particularly the results of key players like VRTX, MRNA, and REGN. If these companies perform well, it could provide a lift to ORMP, but any negative trends could further pressure its performance.

Bottom line

In the 1-3 year outlook, ORMP's performance will depend heavily on sector dynamics and its ability to improve execution. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

2026-09-02	Unavailable	Unavailable	1 / 1

2026-09-03	Unavailable	Unavailable	1 / 1

2026-09-04	Unavailable	Unavailable	1 / 1

2026-09-05	Unavailable	Unavailable	1 / 1

2026-09-06	Unavailable	Unavailable	1 / 1

2026-09-07	Unavailable	Unavailable	1 / 1

2026-09-08	Unavailable	Unavailable	1 / 1

2026-09-09	Unavailable	Unavailable	1 / 1

2026-09-10	Unavailable	Unavailable	1 / 1

2026-09-11	Unavailable	Unavailable	1 / 1

2026-09-12	Unavailable	Unavailable	1 / 1

2026-09-13	Unavailable	Unavailable	1 / 1

2026-09-14	Unavailable	Unavailable	1 / 1

2026-09-15	Unavailable	Unavailable	1 / 1

2026-09-16	Unavailable	Unavailable	1 / 1

2026-09-17	Unavailable	Unavailable	1 / 1

2026-09-18	Unavailable	Unavailable	1 / 1

2026-09-19	Unavailable	Unavailable	1 / 1

2026-09-20	Unavailable	Unavailable	1 / 1

2026-09-21	Unavailable	Unavailable	1 / 1

2026-09-22	Unavailable	Unavailable	1 / 1

2026-09-23	Unavailable	Unavailable	1 / 1

2026-09-24	Unavailable	Unavailable	1 / 1

2026-09-25	Unavailable	Unavailable	1 / 1

2026-09-26	Unavailable	Unavailable	1 / 1

2026-09-27	Unavailable	Unavailable	1 / 1

2026-09-28	Unavailable	Unavailable	1 / 1

2026-09-29	Unavailable	Unavailable	1 / 1

2026-09-30	Unavailable	Unavailable	1 / 1

2026-10-01	Unavailable	Unavailable	1 / 1

2026-10-02	Unavailable	Unavailable	1 / 1

2026-10-03	Unavailable	Unavailable	1 / 1

2026-10-04	Unavailable	Unavailable	1 / 1

2026-10-05	Unavailable	Unavailable	1 / 1

2026-10-06	Unavailable	Unavailable	1 / 1

2026-10-07	Unavailable	Unavailable	1 / 1

2026-10-08	Unavailable	Unavailable	1 / 1

2026-10-09	Unavailable	Unavailable	1 / 1

2026-10-10	Unavailable	Unavailable	1 / 1

2026-10-11	Unavailable	Unavailable	1 / 1

2026-10-12	Unavailable	Unavailable	1 / 1

2026-10-13	Unavailable	Unavailable	1 / 1

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	0	0	0
2026-06-01	0	0	0
2026-07-01	0	0	0
2026-08-01	0	0	0
2026-09-01	0	0	0
2026-10-01	0	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 0 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 16–Oct 15 · 0 recorded

Oramed Pharmaceuticals, Inc. (ORMP) Outlook: What's Priced In | QuarterlyIQ

What could strengthen or challenge Oramed Pharmaceuticals, Inc.’s outlook?

Living FV™

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

Oramed Pharmaceuticals, Inc. outlook in detail

What kind of bet this is

What's priced into Oramed Pharmaceuticals, Inc.

What the fundamentals likely do

What Oramed Pharmaceuticals, Inc. hinges on

Bottom line

Analyst view

Price-target changes

Bottom line